Tazemetostat is a potent and highly selective EZH2 inhibitor that has shown antitumor activity in vitro and in SMARCA4-negative malignant rhabdoid tumor of the ovary52,66. The gene discussed is SMARCA4; the disease is rhabdoid tumor.